News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Consequently, AstraZeneca India and Sun Pharma have now discontinued the Distribution Agreement signed in 2016 and have entered into a Transition Supply Agreement with effect from 28th May 2021
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
The consideration to be paid will be AUD 2.0 mn for 12.5% stake.
The company will review FDA's response and decide on appropriate next steps soon.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
Subscribe To Our Newsletter & Stay Updated
